CO2019007906A2 - Inhibidores de poli-adp ribosa polimerasa (parp) - Google Patents
Inhibidores de poli-adp ribosa polimerasa (parp)Info
- Publication number
- CO2019007906A2 CO2019007906A2 CONC2019/0007906A CO2019007906A CO2019007906A2 CO 2019007906 A2 CO2019007906 A2 CO 2019007906A2 CO 2019007906 A CO2019007906 A CO 2019007906A CO 2019007906 A2 CO2019007906 A2 CO 2019007906A2
- Authority
- CO
- Colombia
- Prior art keywords
- parp
- poly
- inhibitors
- ribose polymerase
- adp ribose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica que comprende un vehículo aceptable farmacéuticamente o un diluyente y un compuesto representado por la siguiente fórmula estructural: . La presente invención también se relaciona con un método para tratar un sujeto con una enfermedad que puede mejorarse mediante la inhibición de la poli(ADP-ribosa)polimerasa (PARP). En la memoria descriptiva se proveen las definiciones de las variables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 | |
| PCT/US2017/068636 WO2018125961A1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019007906A2 true CO2019007906A2 (es) | 2019-10-21 |
Family
ID=61007849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0007906A CO2019007906A2 (es) | 2016-12-30 | 2019-07-23 | Inhibidores de poli-adp ribosa polimerasa (parp) |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11034670B2 (es) |
| EP (1) | EP3562822B1 (es) |
| JP (1) | JP7141399B2 (es) |
| KR (1) | KR102606799B1 (es) |
| CN (1) | CN110167926B (es) |
| AR (1) | AR110706A1 (es) |
| AU (1) | AU2017388376B2 (es) |
| BR (1) | BR112019011676A2 (es) |
| CA (1) | CA3047137A1 (es) |
| CO (1) | CO2019007906A2 (es) |
| CY (1) | CY1124565T1 (es) |
| DK (1) | DK3562822T3 (es) |
| EA (1) | EA201991412A1 (es) |
| ES (1) | ES2875841T3 (es) |
| HR (1) | HRP20210887T1 (es) |
| HU (1) | HUE054382T2 (es) |
| IL (1) | IL267676B (es) |
| JO (1) | JOP20190115B1 (es) |
| LT (1) | LT3562822T (es) |
| MA (1) | MA47165B1 (es) |
| MD (1) | MD3562822T2 (es) |
| MX (1) | MX2019007870A (es) |
| PH (1) | PH12019501529A1 (es) |
| PL (1) | PL3562822T3 (es) |
| PT (1) | PT3562822T (es) |
| RS (1) | RS61895B1 (es) |
| SA (1) | SA519401894B1 (es) |
| SI (1) | SI3562822T1 (es) |
| TW (1) | TWI773718B (es) |
| UA (1) | UA124777C2 (es) |
| WO (1) | WO2018125961A1 (es) |
| ZA (2) | ZA201904004B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022008282A2 (pt) * | 2019-10-30 | 2022-07-26 | Digmbio Inc | Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo |
| CN118076585A (zh) * | 2021-07-23 | 2024-05-24 | 国家医疗保健研究所 | 革兰氏阴性菌外排泵抑制剂 |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| WO2024061768A1 (en) | 2022-09-19 | 2024-03-28 | Basf Se | Azole pesticidal compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070737A2 (en) | 2000-03-20 | 2001-09-27 | Sepracor, Inc. | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof |
| US20030087917A1 (en) | 2000-03-27 | 2003-05-08 | Dorothea Strack | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| EA012416B1 (ru) * | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| EP1924568A1 (en) | 2005-07-15 | 2008-05-28 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
| JPWO2007099828A1 (ja) | 2006-02-23 | 2009-07-16 | 塩野義製薬株式会社 | 環式基で置換された含窒素複素環誘導体 |
| US8349850B2 (en) | 2006-03-28 | 2013-01-08 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| EP3581567A1 (en) | 2011-04-10 | 2019-12-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| US9505749B2 (en) * | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| HUE032846T2 (en) | 2013-07-31 | 2017-11-28 | Merck Patent Gmbh | Oxokinazolinil-butanamide derivatives |
| KR102415436B1 (ko) | 2014-05-07 | 2022-06-30 | 메르크 파텐트 게엠베하 | 헤테로시클릴-부탄아미드 유도체 |
| CN105924434A (zh) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
-
2017
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/ar active
- 2017-12-28 RS RS20210653A patent/RS61895B1/sr unknown
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 SI SI201730772T patent/SI3562822T1/sl unknown
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/hu unknown
- 2017-12-28 BR BR112019011676A patent/BR112019011676A2/pt unknown
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/ko active IP Right Grant
- 2017-12-28 EA EA201991412A patent/EA201991412A1/ru unknown
- 2017-12-28 MA MA47165A patent/MA47165B1/fr unknown
- 2017-12-28 MX MX2019007870A patent/MX2019007870A/es unknown
- 2017-12-28 PL PL17832694T patent/PL3562822T3/pl unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en active Search and Examination
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/ja active Active
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/da active
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/ro unknown
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/lt unknown
- 2017-12-28 ES ES17832694T patent/ES2875841T3/es active Active
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/zh active Active
- 2017-12-28 PT PT178326948T patent/PT3562822T/pt unknown
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 UA UAA201908940A patent/UA124777C2/uk unknown
- 2017-12-29 AR ARP170103718A patent/AR110706A1/es unknown
- 2017-12-29 TW TW106146555A patent/TWI773718B/zh active
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/ar unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/es unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-04 HR HRP20210887TT patent/HRP20210887T1/hr unknown
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019007906A2 (es) | Inhibidores de poli-adp ribosa polimerasa (parp) | |
| CO2018013293A2 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
| CL2018000429A1 (es) | Moduladores de la expresión de kras | |
| CL2018003577A1 (es) | Piridina substituida como inhibidor de dnmt1. | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| CL2015002530A1 (es) | Inhibidores de cdc7 | |
| ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| SV2014004850A (es) | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| GT201700099A (es) | 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1 | |
| CL2017001545A1 (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| AR105400A1 (es) | Inhibidores de jak1 | |
| AR097890A1 (es) | Compuestos de urea | |
| MX2020004545A (es) | Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. |